ASCO 2025: Experts gather to showcase their ground-breaking cancer research
From 30 May to 3 June, the world’s leading oncologists and researchers, including scientists from The Institute of Cancer Research, London, will converge at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting – a premier event in the global cancer research calendar.
Each year, ASCO serves as a crucial platform for unveiling transformative findings, including results from groundbreaking phase III clinical trials, promising early-phase studies, and innovative translational research. Experts also provide insightful commentary on all facets of oncology, shaping the future of cancer care.
The theme for the 2025 ASCO Annual Meeting, "The Art and Science of Cancer Care: From Comfort to Cure," underscores the balance between scientific innovation and compassionate treatment. This year's programme will feature state-of-the-art research, revolutionary therapies, and visionary perspectives designed to inspire and energise the oncology community.
Here are some of the highlights of studies presented by or involving researchers from The Institute of Cancer Research (ICR) and our partners at The Royal Marsden NHS Foundation Trust at ASCO 2025. The times provided below are the local time, in Chicago (GMT-5).
31st May 1st June 2nd June 3rd June
To access the full programme with specific timings and locations visit the ASCO website.
31st May
Oral presentations
- INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).
Abstract: 1003
1.15pm
- Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
Oral Abstract Session
Abstract: 1004
1.15pm
Poster presentations
- Investigating the immunogenomic profile of anal HPV driven disease for novel therapeutic discovery.
Professor Alan Melcher and Professor Trevor Graham
Poster Session
Abstract: 3522. Poster Bd #191
9am
- Factors associated with survival following relapse of high-risk neuroblastoma: A study from the International Neuroblastoma Risk Group (INRG) Data Commons.
Professor Andrew Pearson
Poster Session
Abstract: 10052. Poster Bd #167
9am
- POD1UM-303/INTERAACT2 subgroup analyses and impact of delayed retifanlimab treatment on outcomes in patients with squamous cell carcinoma of the anal canal (SCAC).
Poster Session
Abstract: 3525. Poster Bd #194
9am
- Change in T2-weighted signal intensity, change in tumor volume, and exposure-response analysis in the RINGSIDE phase 2 study of varegacestat in patients with desmoid tumours.
Poster Session
Abstract: 11557. Poster Bd #40
9am
- Moving beyond the traditional two-step approach for prognosis prediction: The BayeSarc model.
Poster Session
Abstract: 11572. Poster Bd #55
9am
- Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.
Poster Session
Abstract: 8611. Poster Bd #91
1.30pm
- Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previously untreated, advanced or metastatic, KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Poster Session
Abstract: TPS8656. Poster Bd #131b
1.30pm
- Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.
Poster Session
Abstract: TPS8666. Poster Bd #136b
1.30pm
- A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation.
Poster Session
Abstract: TPS8667. Poster Bd #137a
1.30pm
1st June
Oral presentations
- A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
Oral Abstract Session
Abstract: 11506
9.45am
- Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study.
Rapid Oral Abstract Session
Abstract: 6012
11.30am
- An open-label, phase Ib trial of the SIRPα inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients (pts) with head and neck squamous cell carcinoma.
Rapid Oral Abstract Session
Abstract: 6019
11.30am
- Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.
Plenary Session
Abstract: LBA4
1pm
- Docetaxel with androgen deprivation therapy (ADT) and radiotherapy (RT) for high-risk localized prostate cancer (HRLPC): An ICECaP individual patient-data (IPD) meta-analysis of randomized controlled trials (RCTs).
Rapid Oral Abstract Session
Abstract: 5013
4.30pm
Poster presentations
- Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC) with 4-year follow-up data.
Poster Session
Abstract: 9554. Poster Bd #37
9am
- Randomized dose evaluation of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with advanced melanoma: Results from RELATIVITY-020.
Poster Session
Abstract: 9526. Poster Bd #9
9am
- Low-dose anti-PD-(L)1 inhibitor strategies: A systematic review.
Poster Session
Abstract: 1526. Poster Bd #279
9am
- Novel analysis of three-year results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy.
Poster Session
Abstract: 7043. Poster Bd #226
9am
- RELATIVITY-020: Intracranial (IC) activity of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with PD-(L)1 refractory melanoma with melanoma brain metastases (MBM).
Poster Session
Abstract: 9525. Poster Bd #8
9am
- Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.
Rapid Oral Abstract Session
Abstract: 8016
4.30pm
2nd June
Oral presentations
- Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study.
Rapid Oral Abstract Session
Abstract: 9515
9.45am
- Subgroup analysis of the phase 2 part of the RINGSIDE phase 2/3 trial of varegacestat for treatment of desmoid tumours.
Rapid Oral Abstract Session
Abstract: 11516
11.30am
- The broad-spectrum KIT inhibitor NB003 and activity in advanced gastrointestinal stromal tumors (GIST): Updated results from a phase 1 study (NCT04936178).
Rapid Oral Abstract Session
Abstract: 11517
11.30am
- Determining the recommended phase 2 dose (RP2D) of dose-intense irinotecan combined with IVA chemotherapy (IRIVA) in newly diagnosed very high risk rhabdomyosarcoma: A phase Ib study within the EpSSG Frontline and Relapsed Rhabdomyosarcoma study (FaR-RMS).
Rapid Oral Abstract Session
Abstract: 10024
3pm
Poster presentations
- Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study.
Poster session
Abstract: 5048. Poster Bd #247
9am
- Versatile-002: Overall survival of HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma patients treated with T cell stimulating immunotherapy PDS0101 and pembrolizumab.
Poster Session
Abstract: 6037. Poster Bd #445
9am
- VERSATILE-003: A phase 3, randomized, open-label trial of PDS0101 and pembrolizumab compared with pembrolizumab for first-line treatment of patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
Abstract: TPS6111. Poster Bd #518a
9am
- A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: The FORTIFI-HN01 study.
Poster Session
Abstract: TPS6113. Poster Bd #519a
9am
- A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: The FORTIFI-HN01 study.
Poster Session
Abstract: TPS6113. Poster Bd #519a
9am
- FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET MAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC).
Poster Session
Abstract: TPS6115. Poster Bd #520a
9am
- Trial in progress (XALute): Phase 3 study of xaluritamig vs investigator’s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC).
Poster Session
Abstract: TPS5118. Poster Bd #313a
9am
- An oral prostate cancer RIPTAC therapeutic in phase 1 for metastatic castrate resistant prostate cancer (mCRPC).
Poster Session
Abstract: TPS5115. Poster Bd #311b
9am
- TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
Poster Session
Abstract: TPS1142. Poster Bd #110a
9am
- Risk factors and causes of early death among patients with germ cell testis tumours (GCTs): An international collaborative study supported by the Global Society of Rare Genitourinary Tumours.
Poster Session
Abstract: 5030. Poster Bd #229
9.am
- AURORA: A single arm, multicentre, phase II clinical trial of atezolizumab immunotherapy for advanced squamous cell carcinoma of the bladder and urinary tract.
Poster Session
Abstract: 4608. Poster Bd #408
9.am
- Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.
Poster Session
Abstract: 6033. Poster Bd #441
9am
- Impact of body mass index (BMI) on efficacy and safety of abemaciclib in breast cancer patients treated in the monarchE trial.
Poster Session
Abstract: 520. Poster Bd #113
9am
- Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.
Poster Session
Abstract: TPS3160. Poster Bd #473b
1.30pm
- Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR-expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study.
Poster Session
Abstract: 2609. Poster Bd #256
1.30pm
- Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR kinase domain mutations (EGFRmut): Initial results from a phase 2a study
Poster Session
Abstract: 2610. Poster Bd #257
1.30pm
- Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR kinase domain mutations (EGFRmut): Initial results from a phase 2a study
Poster Session
Abstract: 2610. Poster Bd #257
1.30pm
- A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors.
Poster Session
Abstract: TPS2670. Poster Bd #316a
1.30pm
- REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynaecologic or genitourinary tumours.
Poster Session
Abstract: TPS3158. Poster Bd #472b
1.30pm
- Phase II dose optimization update with EZH2/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma or endometrial carcinoma.
Poster Session
Abstract: 3102. Poster Bd #417
1.30pm
3rd June
Oral presentations
- Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.
Oral Abstract Session
Abstract: 5001
9.45am
- Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): An ancillary study of the STAMPEDE trials.
Oral Abstract Session
Abstract: 5003
9.45am
- First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.
Oral Abstract Session
Abstract: 7505
9.45am
Join the conversation on Bluesky with the hashtag #ASCO25.
Come back to our website during the conference for more news and stories from the ASCO Annual Meeting.